|
Back to Home » June 2021 News » European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy |
European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy |
June 12, 2021
THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- The Pfizer/BioNTech BNT162b2 vaccine has been approved for the prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is recommended for immunosuppressed patients. However, its efficacy and safety in...
Source URL: https://www.prnewswire.com:443/news-releases/european-hematology-association-humoral-response-to-the-pfizerbiontech-bnt162b2-vaccine-is-impaired-in-patients-receiving-car-t-or-high-intensity-immunosuppressive-therapy-301309978.html
|
|
|
|
